Drug Eruptions

"Drug Eruptions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.

Descriptor ID	D003875
MeSH Number(s)	C17.800.174.600 C20.543.206.380 C25.100.468.380
Concept/Terms	Drug Eruptions Drug Eruptions Drug Eruption Eruption, Drug Eruptions, Drug Dermatitis Medicamentosa Dermatitis, Adverse Drug Reaction Morbilliform Drug Reaction Morbilliform Drug Reaction Drug Reaction, Morbilliform Drug Reactions, Morbilliform Morbilliform Drug Reactions Reaction, Morbilliform Drug Reactions, Morbilliform Drug Maculopapular Exanthem Exanthem, Maculopapular Exanthems, Maculopapular Maculopapular Exanthems Morbilliform Exanthem Exanthem, Morbilliform Exanthems, Morbilliform Morbilliform Exanthems Maculopapular Drug Eruption Drug Eruption, Maculopapular Drug Eruptions, Maculopapular Eruption, Maculopapular Drug Eruptions, Maculopapular Drug Maculopapular Drug Eruptions

Below are MeSH descriptors whose meaning is more general than "Drug Eruptions".

Diseases [C]
Skin and Connective Tissue Diseases [C17]
Skin Diseases [C17.800]
Dermatitis [C17.800.174]
Drug Eruptions [C17.800.174.600]
Immune System Diseases [C20]
Hypersensitivity [C20.543]
Drug Hypersensitivity [C20.543.206]
Drug Eruptions [C20.543.206.380]
Chemically-Induced Disorders [C25]
Drug-Related Side Effects and Adverse Reactions [C25.100]
Drug Hypersensitivity [C25.100.468]
Drug Eruptions [C25.100.468.380]

Below are MeSH descriptors whose meaning is related to "Drug Eruptions".

Below are MeSH descriptors whose meaning is more specific than "Drug Eruptions".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Eruptions" by people in this website by year, and whether "Drug Eruptions" was a major or minor topic of these publications.

Bar chart showing 41 publications over 18 distinct years, with a maximum of 6 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2001	1	0	1
2002	1	0	1
2003	1	1	2
2006	1	2	3
2007	2	2	4
2008	1	1	2
2009	2	1	3
2010	1	0	1
2014	0	1	1
2015	2	0	2
2016	6	0	6
2017	2	3	5
2019	1	1	2
2020	1	0	1
2021	1	0	1
2023	1	0	1
2024	0	4	4

Below are the most recent publications written about "Drug Eruptions" by people in Profiles.

Leventhal J, Madiedo ASA, Andriessen A, Choi JN, Ho A, McLellan B, Mitchell E, Lacouture M. INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events. J Drugs Dermatol. 2024 Dec 01; 23(12):436613s3-436613s14.

View in: PubMed
Loesch AJ, Jin A, Huang S, Motaparthi K, Lee JB, Hsu S. Methotrexate-Induced Epidermal Necrosis. Skinmed. 2024; 22(5):387-389.

View in: PubMed
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clin Cancer Res. 2024 Jul 01; 30(13):2822-2834.

View in: PubMed
Vlachou E, Mamtani R, Hahn NM, Iii BJ, Hoffman-Censits J, Nimgaonkar V. Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin. Clin Genitourin Cancer. 2024 06; 22(3):102090.

View in: PubMed
Gleason L, Hunter E, Cohen A, Suriano J, Nikbakht N. Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review. Dermatol Online J. 2023 Feb 15; 29(1).

View in: PubMed
Anderson HJ, Lee JB. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. Medicina (Kaunas). 2021 Sep 01; 57(9).

View in: PubMed
Labadie JD, Hua X, Harrison TA, Banbury BL, Huyghe JR, Sun W, Shi Q, Yothers G, Alberts SR, Sinicrope FA, Goldberg RM, George TJ, Penney KL, Phipps AI, Cohen SA, Peters U, Chan AT, Newcomb PA. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev. 2021 02; 30(2):404-411.

View in: PubMed
Zarrabi K, Gemmill JAL, Safaee M, Baer L. Managing dermatologic changes of targeted cancer therapy. J Fam Pract. 2019 Jul/Aug; 68(6):334-340.

View in: PubMed
Thiruvengadam S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 2019 09 15; 125(18):3234-3241.

View in: PubMed
Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer. 2018 06; 17(2):85-96.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement